

Application No. 10/584,510
Paper Dated: September 26, 2010
In Reply to USPTO Correspondence of March 24, 2011
Attorney Docket No. 0470-061930

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-17 (Cancelled).

Claim 18 (Currently Amended): A composition for stimulating appetite in a human comprising in a daily dosage form pantothenic acid or an equivalent of pantothenic acid selected from the group consisting of a salt, an ester or an ether of pantothenic acid, pantothenol, (R)-pantoate or a salt or an ester thereof, pantetheine or an ester or an ether thereof and coenzyme A, wherein the daily dosage form of pantothenic acid is 14 to 1000 mg of pantothenic acid, and wherein the daily dosage form of the equivalent of pantothenic acid is an equimolar amount of 14 to 1000 mg of pantothenic acid; and further comprising at least 15 En% proteins that comprise 1.8 to 6 g of methionine per 100 g of the proteins, 5.8 to 12.0 g of lysine per 100 g of the proteins, 1.5 to 4.0 g of tryptophan per 100 g of the proteins and at least 8 g of leucine per 100 g of the proteins, and ~~optionally at least 32-40 En%~~ carbohydrates and/or ~~and~~ at least ~~18-25~~ En% lipids; wherein said composition having a caloric value of at least 100 kcal per daily dosage form.

Claim 19 (Previously Presented): The composition according to claim 18, wherein the proteins are selected from the group consisting of plant proteins, vegetable proteins, cereal proteins, seed proteins and whey proteins.

Claim 20 (Cancelled).

Claim 21 (Cancelled).

Application No. 10/584,510
Paper Dated: September 26, 2010
In Reply to USPTO Correspondence of March 24, 2011
Attorney Docket No. 0470-061930

Claim 22 (Previously Presented): The composition according to claim 18, wherein the proteins comprise serine and glycine in a serine/glycine ratio of 3.4 or higher.

Claim 23 (Previously Presented): The composition according to claim 18, further comprising per daily dosage form 0.2 to 5 g of cysteine or one or more cysteine equivalents selected from the group consisting of cysteamine, L-cystine, L-cystine dimer and N-acetyl cysteine.

Claim 24-29 (Cancelled).

Claim 30 (Currently Amended): The composition according to claim 2718, wherein the lipids comprise at least 12 g saturated fatty acids per 100 g lipids.

Claim 31 (Cancelled).

Claim 32 (Currently Amended): The composition according to claim 2718, wherein the lipids comprise at least 4.0 g myristic acid per 100 g the lipids.

Claim 33 (Cancelled).

Claim 34 (Withdrawn): A method for stimulating appetite in a human, comprising manufacturing a composition comprising proteins (or hydrolysed proteins or amino acids) and pantothenic acid or an equivalent thereof, wherein said composition comprises at least 15 En% proteins (or hydrolysed proteins or amino acids) in a daily dosage of about 14 to 1000 mg pantothenic acid or an equivalent thereof, which equivalent comprises an equimolar amount of about 14 to 1000 mg pantothenic acid, and administering said composition to the human.

Claim 35 (Withdrawn): The method according to claim 34, wherein said method comprises the stabilisation and/or increase of body weight in the human.

Application No. 10/584,510
Paper Dated: September 26, 2010
In Reply to USPTO Correspondence of March 24, 2011
Attorney Docket No. 0470-061930

Claim 36 (Withdrawn): The method according to claim 34, wherein said pantothenic acid or an equivalent thereof is selected from the group consisting of pantothenol, (R)-pantoate or salts or esters thereof, pantothenic acid or salts or esters or ethers thereof, pantetheine or esters or ethers thereof and coenzyme A.

Claim 37 (Withdrawn): The method according to claim 34, wherein said pantothenic acid or an equivalent thereof is selected from the group consisting of pantothenol, (R)-pantoate or salts or esters thereof and pantetheine or esters or salts thereof.

Claim 38 (Withdrawn): The method according to claim 34, wherein said method treats patients suffering from infections, serious liver, kidney or heart disease, cancer of any kind, intestinal obstruction, inflammatory bowel disease, pancreatitis, irritable bowel syndrome, appendicitis, endocrine problems, diabetes, hypothyroidism, autoimmune diseases or disorders, psychological conditions, eating disorders, negative effects of medications or drugs, chemotherapy medications, alcohol, narcotics, antibiotics, diabetes medication, dementia, lung diseases, lung emphysema, traumata following surgery.

Claim 39 (Withdrawn): The method according to claim 34, wherein said method treats nausea during pregnancy.

Claim 40 (Currently Amended): The composition according to claim 18, further comprising per daily dose at least one component selected from the group consisting of 0.2 to 5 g nucleotide or one or more nucleotide equivalents selected from the group consisting of cytidine, uridine and nucleosides; ~~300 to 3000~~ mg folic acid or one or more folic acid equivalents selected from the group consisting of monoglutamate, poly-glutamate 5-methyl-folate, 10-methyl-folate, 5,10-methylene-folate, 5 formyl-folate and 10-formyl-folate; 0.5 to 50 mg vitamin B6 or one or more vitamin B6 equivalents selected from the group consisting of pyridoxine, pyridoxal and pyridoxamine; and 0.5 g of at least one choline source selected from the group consisting of choline, betaine, dimethylglycine and sarcosine.

Application No. 10/584,510
Paper Dated: September 26, 2010
In Reply to USPTO Correspondence of March 24, 2011
Attorney Docket No. 0470-061930

Claim 41 (Previously Presented): The composition according to claim 18, further comprising per daily dose 0.1 to 5 g beta-alanine when the composition comprises the pantothenic acid equivalent (R)-pantoate.

Claim 42 (New): A composition for stimulating appetite in a human comprising in a daily dosage form pantothenic acid or an equivalent of pantothenic acid selected from the group consisting of a salt, an ester or an ether of pantothenic acid, pantothenol, (R)-pantoate or a salt or an ester thereof, pantetheine or an ester or an ether thereof and coenzyme A, wherein the daily dosage form of pantothenic acid is 14 to 1000 mg of pantothenic acid, and wherein the daily dosage form of the equivalent of pantothenic acid is an equimolar amount of 14 to 1000 mg of pantothenic acid; and further comprising at least 15 En% proteins that comprise 1.8 to 6 g of methionine per 100 g of the proteins, 5.8 to 12.0 g of lysine per 100 g of the proteins, 1.5 to 4.0 g of tryptophan per 100 g of the proteins and at least 8 g of leucine per 100 g of the proteins, and optionally at least 32 En% carbohydrates and/or at least 18 En% lipids; wherein said composition having a caloric value of at least 100 kcal per daily dosage form, wherein the composition comprises the lipids in an amount of at least 1.5 g per 100 g composition, and wherein the lipids comprise at least 4.0 g myristic acid per 100 g the lipids.

Claim 43 (New): The composition according to claim 42, wherein the proteins are selected from the group consisting of plant proteins, vegetable proteins, cereal proteins, seed proteins and whey proteins.

Claim 44 (New): The composition according to claim 42, wherein the proteins comprise serine and glycine in a serine/glycine ratio of 3.4 or higher.

Claim 45 (New): The composition according to claim 42, further comprising per daily dosage form 0.2 to 5 g of cysteine or one or more cysteine equivalents selected from the group consisting of cysteamine, L-cystine, L-cystine dimmer and N-acetyl cysteine.

Claim 46 (New): The composition according to claim 42 wherein the caloric value is at least 600 kcal per daily dosage form.

Application No. 10/584,510

Paper Dated: September 26, 2010

In Reply to USPTO Correspondence of March 24, 2011

Attorney Docket No. 0470-061930

Claim 47 (New): The composition according to claim 42, wherein the lipids comprise at least 12 g saturated fatty acids per 100 g lipids.

Claim 48 (New): The composition according to claim 42, further comprising per daily dose at least one component selected from the group consisting of 0.2 to 5 g nucleotide or one or more nucleotide equivalents selected from the group consisting of cytidine, uridine and nucleosides; 300 to 3000 mg folic acid or one or more folic acid equivalents selected from the group consisting of monoglutamate, poly-glutamate 5-methyl-folate, 10-methyl-folate, 5,10-methylene-folate, 5 formyl-folate and 10-formyl-folate; 0.5 to 50 mg vitamin B6 or one or more vitamin B6 equivalents selected from the group consisting of pyridoxine, pyridoxal and pyridoxamine; and 0.5 g of at least one choline source selected from the group consisting of choline, betaine, dimethylglycine and sarcosine.

Claim 49 (New): The composition according to claim 42, further comprising per daily dose 0.1 to 5 g beta-alanine when the composition comprises the pantothenic acid equivalent (R)-pantoate.

Claim 50 (New): A composition for stimulating appetite in a human comprising in a daily dosage form pantothenic acid or an equivalent of pantothenic acid selected from the group consisting of a salt, an ester or an ether of pantothenic acid, pantothenol, (R)-pantoate or a salt or an ester thereof, pantetheine or an ester or an ether thereof and coenzyme A, wherein the daily dosage form of pantothenic acid is 14 to 1000 mg of pantothenic acid, and wherein the daily dosage form of the equivalent of pantothenic acid is an equimolar amount of 14 to 1000 mg of pantothenic acid; and further comprising at least 15 En% proteins that comprise 1.8 to 6 g of methionine per 100 g of the proteins, 5.8 to 12.0 g of lysine per 100 g of the proteins, 1.5 to 4.0 g of tryptophan per 100 g of the proteins and at least 8 g of leucine per 100 g of the proteins, and optionally at least 32 En% carbohydrates and/or at least 18 En% lipids; wherein said composition having a caloric value of at least 100 kcal per daily dosage form; further comprising per daily dose at least one component selected from the group consisting of 0.2 to 5 g nucleotide or one or more nucleotide equivalents selected from the group consisting of cytidine, uridine and nucleosides; 300 to 3000 mg folic acid or one or more folic acid equivalents selected from the group consisting of monoglutamate, poly-glutamate 5-methyl-folate, 10-

Application No. 10/584,510
Paper Dated: September 26, 2010
In Reply to USPTO Correspondence of March 24, 2011
Attorney Docket No. 0470-061930

methyl-folate, 5,10-methylene-folate, 5 formyl-folate and 10-formyl-folate; 0.5 to 50 mg vitamin B6 or one or more vitamin B6 equivalents selected from the group consisting of pyridoxine, pyridoxal and pyridoxamine; and 0.5 g of at least one choline source selected from the group consisting of choline, betaine, dimethylglycine and sarcosine.

Claim 51 (New): The composition according to claim 50, wherein the proteins comprise serine and glycine in a serine/glycine ratio of 3.4 or higher.

Claim 52 (New): The composition according to claim 50, further comprising per daily dosage form 0.2 to 5 g of cysteine or one or more cysteine equivalents selected from the group consisting of cysteamine, L-cystine, L-cystine dimmer and N-acetyl cysteine.

Claim 53 (New): The composition according to claim 50, wherein the caloric value is at least 600 kcal per daily dosage form.

Claim 54 (New): The composition according to claim 50, wherein the lipids comprise at least 12 g saturated fatty acids per 100 g lipids.

Claim 55 (New): The composition according to claim 50, wherein the lipids comprise at least 4.0 g myristic acid per 100 g the lipids.

Claim 56 (New): The composition according to claim 50, further comprising per daily dose 0.1 to 5 g beta-alanine when the composition comprises the pantothenic acid equivalent (R)-pantoate.

Claim 57 (New): A composition for stimulating appetite in a human comprising in a daily dosage form pantothenic acid or an equivalent of pantothenic acid selected from the group consisting of a salt, an ester or an ether of pantothenic acid, pantothenol, (R)-pantoate or a salt or an ester thereof, pantetheine or an ester or an ether thereof and coenzyme A, wherein the daily dosage form of pantothenic acid is 14 to 1000 mg of pantothenic acid, and wherein the daily dosage form of the equivalent of pantothenic acid is an equimolar amount of 14 to 1000 mg of pantothenic acid; and further comprising at least 15 En% proteins that comprise 1.8 to 6 g of methionine per 100 g of the proteins, 5.8 to 12.0 g of lysine per 100 g of

Application No. 10/584,510

Paper Dated: September 26, 2010

In Reply to USPTO Correspondence of March 24, 2011

Attorney Docket No. 0470-061930

the proteins, 1.5 to 4.0 g of tryptophan per 100 g of the proteins and at least 8 g of leucine per 100 g of the proteins, and optionally at least 32 En% carbohydrates and/or at least 18 En% lipids; wherein said composition having a caloric value of at least 100 kcal per daily dosage form, and wherein the whey proteins is acidic whey proteins.

Claim 58 (New): A composition for stimulating appetite in a human comprising in a daily dosage form pantothenic acid or an equivalent of pantothenic acid selected from the group consisting of a salt, an ester or an ether of pantothenic acid, pantothenol, (R)-pantoate or a salt or an ester thereof, pantetheine or an ester or an ether thereof and coenzyme A, wherein the daily dosage form of pantothenic acid is 14 to 1000 mg of pantothenic acid, and wherein the daily dosage form of the equivalent of pantothenic acid is an equimolar amount of 14 to 1000 mg of pantothenic acid; and further comprising at least 15 En% proteins that comprise 1.8 to 6 g of methionine per 100 g of the proteins, 5.8 to 12.0 g of lysine per 100 g of the proteins, 1.5 to 4.0 g of tryptophan per 100 g of the proteins and at least 8 g of leucine per 100 g of the proteins, and optionally at least 32 En% carbohydrates and/or at least 18 En% lipids; wherein said composition having a caloric value of at least 100 kcal per daily dosage form, further comprising per daily dose 0.1 to 5 g beta-alanine when the composition comprises the pantothenic acid equivalent (R)-pantoate.